CYSTOPURIN Granules for oral solution 3 Grams
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
05-05-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
POTASSIUM CITRATE
Available from:
G & A Licensing Limited
Dosage:
3 Grams
Pharmaceutical form:
Granules for oral solution
Authorization date:
2010-04-16
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Cystopurin 3g Granules for Oral Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Contains Potassium Citrate 3g/sachet
Excipients-Contains Aspartame (E951), sucrose and ethanol
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Granules for oral solution
_Product imported from the UK:_
Pink-brown granules for dissolution in water.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the symptomatic relief of mild urinary tract infections (cystitis).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
For oral administration.
_Adults (including the elderly and children over 6 years):_
One 3 g sachet, dissolved in 200 ml of cold water, three times daily for two days. All six sachets must be taken to
complete the treatment.
Not recommended for children under six years of age.
4.3 CONTRAINDICATIONS
Use in patients with renal insufficiency.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
This product is intended for short term treatment. Patients should seek doctor's advice if symptoms persist after 48
hours treatment.
This product should only be used with caution in patients with cardiac disease.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 26/10/2011_
_CRN 2107054_
_page number: 1_
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
Concurrent administration of potassium sparing diuretics or ACE inhibitors may lead to hyperkalaemia. The activity of
cardiac glycosides is to some extent dependant upon serum potassium levels. Therefore, there is a possible interaction
and caution is advised.
4.6 FERTILITY, PREGNANCY AND LACTATION
There is no information available from animal studies and there is no epid
Read the complete document
